2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Journal of Thrombosis and Haemostasis · 2024-06 · 22 (6) · 1779-1797
DOI: 10.1016/j.jtha.2024.02.011 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-06. Verfasst von Sam Schulman und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Obstetrics and Gynecology and Perinatal Medicine, I.M. Sechenov…. Hauptthemen laut MEDLINE: COVID-19, Fibrinolytic Agents. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Society on Thrombosis and Haemostasis Inc.
Abstract (Originalsprache)
Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most of the previous recommendations. We used again the American College of Cardiology Foundation/American Heart Association methodology for assessment of level of evidence (LOE) and class of recommendation (COR). Five recommendations had the LOE upgraded to A and 2 new recommendations on antithrombotic treatment for patients with COVID-19 were added. Furthermore, a section was added to answer questions about COVID-19 vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT), for which studies have provided some evidence. We only included recommendations with LOE A or B. Panelists agreed on 19 recommendations, 4 for nonhospitalized, 5 for noncritically ill hospitalized, 3 for critically ill hospitalized, and 2 for postdischarge patients, as well as 5 for vaccination and VITT. A strong recommendation (COR 1) was given for (a) use of prophylactic dose of low-molecular-weight heparin or unfractionated heparin in noncritically ill patients hospitalized for COVID-19, (b) for select patients in this group, use of therapeutic-dose low-molecular-weight heparin/unfractionated heparin in preference to prophylactic dose, and (c) for use of antiplatelet factor 4 enzyme immunoassays for diagnosing VITT. A strong recommendation was given against (COR 3) the addition of an antiplatelet agent in hospitalized, noncritically ill patients. These international guidelines provide recommendations for countries with diverse healthcare resources and COVID-19 vaccine availability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Obstetrics and Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Electronic add…
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
- Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.
- Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
- Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Transfusion Medicine and Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy; University of Milan Bicocca, Monza, Italy.
Förderung
- International Society on Thrombosis and Haemostasis Inc
Zitieren
APA
Schulman, S., Arnold, D. M., Bradbury, C. A., Broxmeyer, L., Connors, J. M., Falanga, A., Iba, T., Kaatz, S., Levy, J. H., Middeldorp, S., Minichiello, T., Nazy, I., Ramacciotti, E., Resnick, H. E., Samama, C. M., Sholzberg, M., Thachil, J., Zarychanski, R., Spyropoulos, A. C., & International Society on Thrombosis and Haemostasis (2024). 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis, 22(6), 1779-1797. https://doi.org/10.1016/j.jtha.2024.02.011
Vancouver
Schulman S, Arnold DM, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis. 2024;22(6):1779-1797. doi:10.1016/j.jtha.2024.02.011
BibTeX
@article{Schulman2024,
author = {Schulman, Sam and Arnold, Donald M and Bradbury, Charlotte A and Broxmeyer, Lisa and Connors, Jean Marie and Falanga, Anna and Iba, Toshiaki and Kaatz, Scott and Levy, Jerrold H and Middeldorp, Saskia and Minichiello, Tracy and Nazy, Ishac and Ramacciotti, Eduardo and Resnick, Helaine E and Samama, Charles Marc and Sholzberg, Michelle and Thachil, Jecko and Zarychanski, Ryan and Spyropoulos, Alex C and International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis},
title = {2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
volume = {22},
number = {6},
pages = {1779--1797},
doi = {10.1016/j.jtha.2024.02.011}
}
EUVIMED